High-Throughput Platform for Fast-Acting Covalent Protein Therapies

Why It Matters

The ability to achieve rapid, irreversible target engagement overcomes the kinetic mismatch that has limited covalent protein drug development, opening a new class of biologics with improved efficacy and safety for cancer and infectious diseases.

Key Takeaways

• Yeast display platform screens millions of covalent protein variants.
• IB101 covalent PD‑L1 antagonist outperforms antibodies in mice.
• Covalent IL‑18 variant enhances immune signaling without toxicity.
• Platform also creates SARS‑CoV‑2 RBD covalent inhibitor.
• Accelerated covalent bonding matches rapid in vivo clearance.

Pulse Analysis

Covalent small‑molecule drugs have reshaped oncology by locking onto targets, yet translating that irreversible chemistry to protein therapeutics has been hampered by a kinetic mismatch: engineered miniproteins clear from the bloodstream in minutes while the covalent reaction proceeds over hours. This disparity has prevented the development of durable biologics that can leverage the potency of covalent binding. Researchers have therefore sought strategies to pre‑organize reactive warheads within protein scaffolds, aiming to compress bond‑formation timescales without raising intrinsic reactivity that could cause off‑target effects.

The Westlake team answered this need with a yeast‑surface‑display platform that couples chemoselective modification to high‑throughput screening of both crosslinker chemistries and protein sequence libraries. By iterating over millions of variants, they identified configurations where the warhead is positioned in a binding pocket, dramatically accelerating covalent attachment. The resulting molecules—IB101, a covalent PD‑L1 antagonist, and IB201, a covalent IL‑18 cytokine—demonstrated superior antitumor activity and immune activation in mouse models while retaining short systemic half‑lives. A parallel effort produced a covalent inhibitor of the SARS‑CoV‑2 spike receptor‑binding domain, underscoring the platform’s versatility across therapeutic modalities.

For the biotech industry, this technology promises a new pipeline of fast‑acting biologics that combine the specificity of proteins with the durability of covalent drugs. Accelerated bond formation enables effective target engagement before clearance, potentially reducing dosing frequency and improving safety profiles. Companies developing checkpoint inhibitors, cytokine therapies, or antiviral proteins can leverage the platform to generate candidates with differentiated pharmacodynamics, attracting investment and expediting regulatory pathways that favor novel mechanisms of action. As the market for next‑generation immunotherapies expands, the ability to engineer covalent protein drugs may become a critical competitive advantage.